Categories: Tech

CORRECTION — Innventure announces strategic investment in Accelsius by Johnson Controls

This press release was corrected to specify that Innventure’s private placement was unrelated to the strategic investment in Accelsius by Johnson Controls.

ORLANDO, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) — Innventure, Inc. (NASDAQ: INV) is pleased to announce a strategic investment in Accelsius, a provider of two-phase, direct-to-chip liquid cooling systems, by Johnson Controls (NYSE: JCI). JCI announced the transaction earlier today in a press release that can be found here.

In an unrelated transaction, Innventure also announces the closing of a private placement of Innventure common stock and warrants anchored by CastleKnight. The gross proceeds from this transaction were $9.75 million. This capital raise, along with the recently disclosed issuance to Yorkville of convertible debentures in an aggregate principal amount of up to $15 million, provides working capital to support Innventure’s ongoing business operations.

About Innventure
Innventure founds, funds, and operates companies with a focus on transformative, sustainable technology solutions acquired or licensed from multinational corporations. As owner-operators, Innventure takes what it believes to be breakthrough technologies from early evaluation to scaled commercialization utilizing an approach designed to help mitigate risk as it builds disruptive companies it believes have the potential to achieve a target enterprise value of at least $1 billion. Innventure defines ‘‘disruptive’’ as innovations that have the ability to significantly change the way businesses, industries, markets and/or consumers operate.

Media Contact: Laurie Steinberg, Solebury Strategic Communications
press@innventure.com

Investor Relations Contact: Sloan Bohlen, Solebury Strategic Communications
investorrelations@innventure.com

GlobeNews Wire

Recent Posts

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

ZUG, Switzerland, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Ms. Kazem brings extensive and global expertise…

7 days ago

Novartis Vanrafia Phase III data support slowing of kidney function decline in patients with IgA nephropathy

Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN…

2 weeks ago

January Commercial Chapter 11 Filings Increase 76% Over 2025

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- There were 956 commercial Chapter 11 filings…

3 weeks ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

Basel, February 6, 2026 – Novartis today broke ground on a new, state-of-the-art global Biomedical…

3 weeks ago

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjgrens disease

Basel, January 16, 2026 – Novartis today announced that the US Food and Drug Administration (FDA)…

1 month ago

Personar Appoints Former Genius Sports COO Eric Stevens as Chief Operating Officer to Scale Award-Winning Sports Technology Platform

Tuesday 13 January, 2026 LONDON – Tuesday, January 13, 2026 – Personar, the AI sports…

1 month ago